30
CARDIOVASCULAR
hamburger

Platform Matters—Unique Interwoven Design Of Supera™ Stent

Breakthrough Technology in Stent Platform

The Supera™ Stent’s unique design results in a platform with features unmatched among standard nitinol peripheral stents:

Strength—its high resistance to compression1

high resistance to compression

Low chronic outward force against vessel walls2

Supera low chronic outward force

High flexibility,3 which allows for fracture resistance4

High flexibility and fracture resistance

View the Supera™ Stent Difference

The interwoven nitinol design provides high structural integrity and kink resistance, producing the features that set the Supera™ Stent apart.

Video showing Supera™ Stent flexibility

Offering Unparalleled Strength for Compression Resistance

The Supera™ Stent exhibits more than 4 times the compression resistance of all other self-expanding nitinol stents.2 Benchtop testing with the 5 pounds of force results in compression of a standard laser-cut nitinol stent (below left). When the same force is applied to the Supera™ Stent, it retains its circular form (below right).

In the clinical setting, those results are illustrated by being deployed in the same patient and same vessel via the angiogram and intravacular ultrasound (IVUS) images below. In the IVUS images, note the compression of the standard nitinol stent, while the Supera™ Stent was able to retain its circular shape. Such performance is particularly important in heavily calcified lesions.

Supera™ Stent offers unparalleled compression resistance

Angiogram and IVUS images courtesy of Dr. Andrej Schmidt.

Exerting the Least Chronic Outward Force on the Vessel Wall2

While laser-cut nitinol stents are designed and required to be oversized for deployment, the Supera™ Stent is unique in that it is sized 1:1 with the vessel diameter. So as seen in the image below, the laser-cut stents inherently exert force on the vessel wall throughout the lifetime of the stent, which in turn can result in endovascular injury over the long term. The lower chronic outward force (COF) with the Supera™ Stent results in fewer vessel injuries.2,4

Standard Nitinol Stent (SNS) Designs

Pushes against the vessel to open, through lifetime of SNS

STENT OVERSIZING   HIGH COF2 VESSEL INJURY4
Chronic outward force (COF) is exerted on vessel by self-expanding stents due to inherent oversizing

Supera™ Stent

1:1 sizing allows to scaffold the vessel to maintain open

SIZING 1:1   LOW COF2 MINIMAL VESSEL
INJURY4
Supera™ Stent is sized 1:1 with the prepared vessel and therefore has minimal chronic outward force

Providing Unparalleled Flexibility3 and Zero Fractures4-20

Other self-expanding nitinol stents are fashioned from a rigid, inflexible tube that is laser-cut. As shown in the photo below, due to design and materials properties, some laser cut stents are less likely to conform to a dynamic vascular environment and can potentially kink and fracture in tortuous vessels (left).

Laser-Cut Stents

L-R: other nitinol stents can kink; Supera™ Stent has great flexibility

Supera™ Stent

L-R: other nitinol stents can kink; Supera™ Stent has great flexibility

With the Supera™ Stent, however, individual flexible nitinol wires are interwoven for unparalleled flexibility,3 excellent kink resistance, and the ability to mimic the natural movement of the anatomy21-23 (right).

Consequently, data on over 2,000 patients published in 17 studies have shown that at 1 year the Supera™ Stent has zero fractures.4-20

17 studies show 0 fractures at 1 year with Supera™ Stent
  • REFERENCES

    1. Test(s) performed by and data on file at Abbott.
    2. Competitors tested include Astron Pulsar-18, Complete SE, EverFlex, Innova, LifeStent, Misago, S.M.A.R.T., and Zilver PTX. Test(s) performed by and data on file at Abbott.
    3. Flexibility is defined as kink resistance.  Competitors tested include Astron Pulsar-18, Complete SE,  EverFlex, Innova, LifeStent, Misago, S.M.A.R.T., and Zilver PTX. Test(s) performed by and data on file at Abbott.
    4. Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267.
    5. Brescia AA. et al., J Vasc Surg. 2015 Jun;61(6):1472-8
    6. Chan YC. et al., J Vasc Surg. 2015 Nov;62(5):1201-9.
    7. Dumantepe M. Vasc Endovascular Surg. 2017 Jul;51(5):240-246.
    8. George JC. et al., J Vasc Interv Radiol. 2014 Jun;25(6):954-61.
    9. Goltz JP. et al., J Endovasc Ther. 2012 Jun;19(3):450-6.
    10. León LR Jr. et al., J Vasc Surg. 2013 Apr;57(4):1014-22.
    11. Montero-Baker M. et al., J Vasc Surg. 2016 Oct;64(4):1002-8.
    12. Myint M. et al., J Endovasc Ther. 2016 Jun;23(3):433-41.
    13. Palena LM. et al., J Endovasc Ther. 2018 Oct;25(5):588-591.
    14. Scheinert D. et al., JACC Cardiovasc Interv. 2013 Jan;6(1):65-71.
    15. Scheinert D. et al., J Endovasc Ther. 2011 Dec;18(6):745-52.
    16. Steiner S. et al., J Endovasc Ther. 2016 Apr;23(2):347-55.
    17. Werner M. et al., EuroIntervention. 2014 Nov;10(7):861-8.
    18. San Norberto EM. et al., Ann Vasc Surg. 2017 May;41:186-195.
    19. Teymen B. et al., Vascular. 2018 Feb;26(1):54-61.
    20. Bhatt H. et al., Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):512-515.
    21. Arena F. et al., J Vasc Med Surg. 2013:1;116.
    22. Chen Y. et al., J Vasc Surg 2014;59:384-91.
    23. Test(s) performed by and data on file at Abbott

MAT-2001695 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

True
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.